alexa TBSURE: An Improved Multiplex Real-Time PCR for TB Detection and Differentiation from Nontuberculous Mycobacterial Diseases in Adult Indian Population
ISSN: 2161-1068
Mycobacterial Diseases
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

TBSURE: An Improved Multiplex Real-Time PCR for TB Detection and Differentiation from Nontuberculous Mycobacterial Diseases in Adult Indian Population

Aakansha Bhawsar1#, Rajni Garg1,2,#, Jasbeer Chhabra3, Rajendra Prasad2, Atul Thatai3* and Rakesh Bhatnagar1*

1BSL3 Laboratory, School of Biotechnology, Jawaharlal Nehru University, New Delhi, India

2Amity Institute of Biotechnology, Manesar, Gurgaon, Amity University, Haryana, India

3Dr. Lal Path Labs Ltd., National Reference Laboratory, Rohini, New Delhi, India

#These Authors Contributed Equally

*Corresponding Author:
Bhatnagar R
BSL3 Laboratory, School of Biotechnology, Jawaharlal Nehru University
New Delhi-110067, and India
Tel: +91 11 26704079
E-mail: [email protected]
Thatai A
Dr. Lal Path Labs Ltd., National Reference Laboratory
Rohini, New Delhi -110085, India
Tel: 9810205412
E-mail: [email protected]

Received date: December 08, 2016; Accepted date: February 22, 2017; Published date: March 1, 2017

Citation: Bhawsar A, Garg R, Chhabra J, Prasad R, Thatai A, Bhatnagar R (2017) TBSURE: An Improved Multiplex Real-Time PCR for TB Detection and Differentiation from Nontuberculous Mycobacterial Diseases in Adult Indian Population. Mycobact Dis 7:232. doi: 10.4172/2161-1068.1000232

Copyright: © 2016 Bhawsar A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Mycobacterial Diseases


Background: Tuberculosis (TB), an infectious disease caused by bacterium Mycobacterium tuberculosis, has crossed the borders of developing nations and has now emerged as disease of global emergency due to an alarming increase in cases of co-infection with human immunodeficiency virus (HIV). Conventional diagnostics used for TB diagnosis like microscopy and culture although reliable are time consuming. Rapid diagnosis of the disease is required for early commencement of treatment of TB patients. The diagnosis of extra pulmonary tuberculosis (EPTB) is more troublesome due to limited accessibility of infection sites and lack of accurate differentiation from other granulomatous diseases. Currently, WHO advises use of Xpert MTB/RIF assay for EPTB diagnosis, but this assay cannot be used in resource constrained settings prevalent in most of parts of India.

Aim: We aimed to develop a multiplex real-time PCR assay which not only detects Mycobacterium tuberculosis complex (MTBC) but also differentiates them from nontuberculous mycobacteria (NTM).

Methods: For development and validation of TBSURE, we included 3, 709 EPTB samples from adult Indian patients suspected for TB. TBSURE is a real time PCR diagnostic which uses three Taqman probes based on IS6110, MPB64 and 16S rRNA genes. The sensitivity and specificity of TBSURE was compared with the goldstandard culture test and XpertMTB/RIF assay for TB detection.

Results and Conclusion: TBSURE gave a sensitivity of 92% and specificity of 91% as compared to Xpert MTB/RIF assay, when samples from TB suspected individuals were subjected to both the tests. As compared to AFB culture, TBSURE gave a sensitivity of 93.1% and specificity of 96.5%. Thus, TBSURE is an in-house efficient and affordable diagnostic test for EPTB diagnosis.


Tuberculosis; Multiplex real-time PCR; MTBC; NTM; Xpert MTB/RIF assay


During the last decade, resurgence of TB has been seen in both developed and developing nations; especially due to increase in cases of co-infection with human immune deficiency virus (HIV). India contributes to approximately one quarter of global TB burden. In 2015, 2.2 million new cases of active TB were detected in India, out of global incidence of 9.6 million [1].

Rapid and reliable diagnosis of disease is required for early start of lengthy treatment for TB. Acid fast bacterial (AFB) culture followed by Ziehl-Neelsen staining of Mycobacteria is time consuming and often not able to differentiate between tuberculous and nontuberculous mycobacteria. The EPTB is even more difficult to detect by AFB culture and smear methods due to low bacillary load. The paucibacillary nature of EPTB, lack of uniform distribution of mycobacteria at various sites in the body makes the early diagnosis of this disease even more cumbersome [2,3].

The diagnosis of smear positive pulmonary tuberculosis (PTB) has been established but that of EPTB, smear negative PTB and HIV-TB co-infection is still posing many challenges to scientists throughout the world. The routinely used smear microscopy for diagnosis of EPTB fails to distinguish between MTBC and NTM. EPTB samples have been diagnosed by a variety of tests like smear microscopy, Interferon gamma release assay (IGRA), histopathology, tuberculin skin test, culture identification, each having its own limitation. These tests also fail to distinguish between MTBC infection and other granulomatous diseases like sarcoidosis, leprosy, systemic lupus erythematosus and NTM [4,5].

Molecular methods like polymerase chain reaction (PCR) are increasingly replacing old methods for EPTB diagnosis due to their precision and lack of need for BSL3 laboratory. Real-time PCR (qPCR) is widely used for laboratory diagnoses of infectious diseases caused by viruses, bacteria, parasites or fungi [6]. qPCR has further advantages, including high sensitivity, reproducibility, accuracy, reduced false positives due to reduced contamination and does not require running of agarose gel after every reaction, as in conventional PCR reactions.

The insertion sequence IS6110 has emerged as an attractive target for molecular detection of MTBC in a large number of diagnostic methods as it is the most prolific IS element in the genome of the MTBC bacteria [7-10]. A meta-analysis and meta-regression study established that use of IS6110 probes in PCR, significantly increased the reliability of PCR based diagnostics for MTBC [11]. The presence in multiple copies in mycobacterial genome made this sequence a standard for RFLP analysis to distinguish between isolates of MTBC.

However, the number of isolates with zero copy of IS6110 (zero band in RFLP analysis) are now not only restricted to South-East Asia, but a lot of such cases have been reported in different parts of USA as well, leading to false-negative results affecting the sensitivity of the assay [12,13]. Therefore, use of other probes in addition to IS6110, appears to be a method of choice, to increase specificity of the test. Singh et al. recently developed a multiplex PCR test which uses IS6110, in combination with two other unrelated genes like namely, HSp65 and DNAJ. This test proved to be better and rapid than AFB culture and smear microscopy, but it had a sensitivity ranging from 73.33% to 84.61%, and the specificity of 80% [14]. For diagnosis of different types of EPTB, IS6110 has been used by different groups to give a specificity of around 100%, but none of these tests gave a good sensitivity [15-18]. There are two reports by Sharma et al. one on TB meningitis and other on osteoarticular TB that uses multiplex PCR using IS6110, MPB64, in conjunction with a 38KDa protein respectively [19,20].

In order to improve sensitivity of current diagnostic procedure for TB, in TBSURE, we have introduced a second probe, MPB64 (a secretory protein) from Mycobacterium tuberculosis H37Rv, which has a role in virulence of the bacterium [21,22]. Both the probes were labeled with FAM-TAMRA to increase sensitivity. MPB64 helps in selection of those MTBC strains in which IS6110 is absent. MPB64 has been used previously also to detect Mycobacterium tuberculosis in pleural and meningeal tuberculosis cases, where it gave a sensitivity of 70% and specificity of 88% [23]. We have also used another probe for 16S rRNA for differentiation of mycobacteria from NTM. Here in this study, we have used TBSURE for 3,709 EPTB samples including Pleural fluids (664), body fluids (402), pus (754), CSF (291), endometrium (1152), ascites fluid (1), urine (228) and miscellaneous samples (217). We have created three different groups of patients and tested them by TBSURE and culture method; TBSURE and Xpert MTB/RIF assay and with all the three methods. Additionally, we have also done Sanger sequencing on 109 patient samples to detect rifampin resistance in MTBC positive samples, so as to compare its sensitivity with gold standard Haintest and Xpert MTB/RIF assay.

Materials and Methods

Ethics statement

All the experiments on virulent Mycobacterial cultures were done in DBT sponsored BSL3 Laboratory, School of Biotechnology, Jawaharlal Nehru University, New Delhi. All the experiments on human samples were done in compliance with the guidelines of Good Society for Ethical Research, Shahdra, and New Delhi, India.

Sample size

A total of 3,709 EPTB samples of different origins were collected from adult patients of Indian origin for TB detection and differentiation from NTM. Out of these samples, 3002 samples were tested by TBSURE and AFB culture, 585 samples were tested with TBSURE and Xpert MTB/RIF assay and 122 samples were tested by all three methods. Rifampin resistance was tested in 109 patient samples by Sanger sequencing, Xpert MTB/RIF assay and Hain’s assay. Table 1 shows the types of EPTB samples collected at various collection centres of Dr. LalPathLabs Ltd. and different methods used for their diagnosis.

Sample Type TBSURE
Xpert MTB/RIF vs.
Pleural fluid 256 392 16
Body Fluids 114 288 -
Pus 284 436 34
Cerebrospinal Fluid (CSF) 74 216 1
Endometrium - 1152 -
Ascites Fluid - - 1
Urine - 227 1
Misc. 85 132 -
Total 813 2843 53

Table 1: Types and numbers of extra-pulmonary tuberculosis samples diagnosed through various tests. Body Fluid types include samples of various origins like Peritoneal, Pericardial, Synovial and Gastric juice. Miscellaneous samples include lymph node, fine needle aspirates, ET secretion and trans-bronchial needle aspirates.


10-100 ml of urine sample, body fluids, ascites fluid, pus and pleural fluid and 2 ml CSF samples were collected in sterile disposable containers. For biopsies, fresh tissue or bone tissue was kept in normal saline. All the samples were transported to the National Reference Laboratory, Dr. LalPathlabs Ltd. at 4?C. Paraffin embedded tissue block was cut in 8-10 μm sections and kept at room temperature. For bone tissue samples of size 250 mm3, decalcification was done 3-4 times, by adding 10 ml of 0.5 M EDTA, pH 8.0, after washing and centrifugation the samples were proceeded for DNA isolation, by using guanidine thiocyanate method.

Target population

The samples of different origins were collected from adult patients of Indian origin clinically suspected for EPTB.

Study setting

This study compared TB diagnostic tools and estimated levels of misdiagnosis in a resource limited setting. Furthermore, we estimated the diagnostic utility of three-different techniques in TB diagnostics viz GeneXpert, Culture and Hain assay.

Case definition

Tuberculosis suspect: Any person who presents with symptoms or signs suggestive ofEPTB. The most common symptom of EPTB is pain and swelling of the involved area which may be accompanied by other constitutional symptoms like loss of appetite, weight loss, fever, night sweats, and fatigue.

Case of tuberculosis: A definite case of EPTB (defined below) or one in which a health worker (clinician or other medical practitioner) has diagnosed EPTB and has decided to treat the patient with a full course of TB treatment.

Definite case of tuberculosis: A patient with Mycobacterium tuberculosis complex identified from a clinical specimen, either by culture or by a newer method such as GeneXpert.

Inclusion criteria

Patients clinically suspected of tuberculosis presenting symptoms or signs suggestive of EPTB. Most commonly patients present enlarged lymph nodes in case of TB lymphadenitis; headache, neck stiffness, altered mental status, and cranial nerve abnormalities in case of meningeal TB; abdominal swelling, pain, fever, change in bowel habits and haem-positive stool in case of abdominal TB and dysuria, haematuria, urinary frequency, pelvic pain, menstrual disorders or infertility in women in case of genitourinary TB.

Exclusion Criteria

Samples received without any clinical history or without correct requisition and consent form. Samples were also excluded if the volume of the sample is inadequate or the sample is not transported in sterile and refrigerated conditions. Blood samples were also excluded from the study.

Pre-treatment of extra- pulmonary tuberculosis samples

For all the samples except bone tissue samples, the samples were mixed thoroughly for 15 sec on a vortex mixer and centrifuged at 10,000 rpm for 10 min. The supernatant was discarded and the pellet was incubated with decontamination liquid without N-acetyl Lcysteine (NALC) for 10 min. The sample was centrifuged again, the supernatant was discarded and 1 ml of 10 mM Tris-HCl, pH 8.0 was added to each vial. It was again centrifuged at 20°C and the supernatant was aspirated. 200 μl of proteinase K solution was added and incubated at 56°C for 30 min and proteinase K was inactivated at 95°C for 10 min. For paraffin embedded tissue, the proteinase K treatment was given overnight and then proceeded with DNA isolation. In case of hemolysed sample, dehemoglobinisation was performed using whole blood lysis buffer (BioRAD) as per manufacturer’s instructions, after decontaminating with decontamination fluid containing N-acetyl-L-cysteine (NALC) as described above.

DNA isolation and quantification

Genomic DNA was isolated from the pre-treated samples using Guanidine thiocyanate method. 1 ml of lysis buffer 1 containing 480 g/l guanidine thiocyanate, 1% Triton X 100 in Tris EDTA buffer was added to each reaction vial. The Celite suspension was thoroughly mixed on a vortex mixer and 50 μl of the suspension was pipetted to each reaction vial. The reaction vials were mixed on a vortex mixer and shaken for 10 min and were then centrifuged at 10,000 rpm for 1 min. The supernatant thus obtained was discarded and to the remaining pellet, 1 ml of lysis buffer 2 containing 480 g/l guanidine thiocyante in Tris buffer (pH 6.4) was added and mixed thoroughly. The pellet was washed with 70% ethanol, dried and suspended in 10 mM Tris-HCl. The vials were incubated for 10 min in a water bath at 56?C. The contents of the vials were mixed on a vortex to resuspend the Celite and centrifuged at 10,000 rpm for 2 min. The supernatant thus obtained was used for PCR. Figure 1 shows pictorial representation of methods used in TBSURE.


Figure 1: Steps in using TBSURE test. The clinical samples were collected in sterile and refrigerated conditions. Pretreatment and decontamination of samples being processed was done using NAcetyl- L-Cysteine (NALC)-NaOH method. The genomic DNA was isolated using guanidine thiocyanate method and real-time PCR was performed. The reaction curves were analysed for detection and differentiation of MTBC and NTM.

Real Time PCR

For detection of MTBC and NTMs, multiplex real-time PCR was set up in 96 well plate. Each reaction mix was of 15 μl containing 12.5 μl Premix Ex Taq (Takara Biosciences, USA), 0.5 μl ROX and 2 μl Primer and probe mix. To this reaction mix, 10 μl DNA sample was added. Each run contained a direct positive PCR control (from genomic DNA of Mycobacterium tuberculosis H37Rv), sensitivity control, no template control (NTC) and negative sample preparation control. For direct positive PCR control, the genomic DNA was suitably diluted after taking the OD260, to yield 40 fg/μl, 10 μl of which (=400 fg) was used to put up positive control. This control monitored the run for correct reconstitution and amplification of master mix.1:10 dilution of above was added to the master mix to serve as the sensitivity control to monitor sensitivity of the run. Each DNA sample was used for TBSURE as well as internal amplification control (IAC) real time PCR reactions separately. Vector and primers for IAC ‘lambda phage’ were obtained from TIB Mol Biol., Germany. 50,000 copies of lambda phage DNA was spiked in each sample and negative water control. DNA was isolated and amplified with lambda phage primers. This control was used to monitor the DNA isolation procedure and presence of inhibitors in the sample. For IAC reaction, each reaction vial contained 12.5 μlSYBR® Premix Ex Taq™,0.5 μl SYBR® ROX (50X), 2 μl primer mix to give a total volume of 15 μl, to which 10 μl DNA sample was added. The cycling parameters used for TBSURE are 95?C for 15 sec, 60?C for 30 sec and 60?C acquiring at FAM and JOE. The cycling parameters for IAC PCR are 95?C for 15 sec, 60?C for 30 sec and 60?C acquiring at SYBR, followed by melting curve analysis. For melting curve analysis, each cycle started from 60 ?C and the temperature was increased by 0.5?C till 95?C.

Specificity of the test

The specificity of all the primers and probes was checked by amplification of DNA from all the five members of MTBC namely, M. tuberculosis , M. bovis , M. microti , M. africanum and M. canetti . The genus specific probe was used to check the specificity. DNA from nonmycobacterial genera like M. avium , M. fortuitum , M. xenopie and M. boviswas used for amplification with test primers and probes as well as with the genus specific probes.

Limit of detection (LOD) and reproducibility

Genomic DNA was extracted from Mycobacterium tuberculosis H37Rv culture and OD260 was measured and the 10-fold dilution of DNA was made and so as to give 2,00,000 to 2 genome equivalents per 10 μl as one bacterium has approximately 10 fg of DNA. The dilutions were tested in triplicate, and the LOD was determined as the dilution at which all replicates were positive.

Xpert MTB/RIF assay

The Xpert MTB/RIF assay (Cepheid Inc., Sunnyvale, CA, USA) was performed according to the manufacturer’s instructions. This assay is a cartridge based, fully automated, rapid and real-time based nucleic acid amplification test which is used for the detection of MTBC and rifampin resistance in an MTB infection. The device amplifies a region of the rpoB gene which is specific for MTB. It also determines rifampin resistance by using molecular beacons for mutations within the rifampin resistance determining region [24].

Culture of Mycobacterium tuberculosis from EPTB samples

After pre-treatment of samples with N-acetyl-L-cysteine and sodium hydroxide method and centrifugation step, the specimens containing bacterial load was resuspended in phosphate buffer, pH 6.8 and this was used to inoculate culture media in the MGIT™ (mycobacterial growth indicator) 960 tubes and incubated at 37?C. The results were recorded as positive or negative in numerical growth units, based on oxygen consumption, using BD BACTEC ™ MGIT ™ 960 System following manufacturer’s instructions [25].

Sanger sequencing for rifampin resistance determination

DNA was extracted from decontaminated samples as described earlier. Rifampin resistance determining region of rpoB gene was PCR amplified using specific primers. Each reaction was of 25 μl containing 0.8 picomoles of primers, 1X SYBR mix, 0.5 μl ROX, template DNA and nuclease free water. An annealing temperature of 65°C was used and the template DNA was amplified for 2 min at 72?C for 40 cycles. Sequencing of the PCR products was done on ABI 3500 Dx Genetic Analyser and Seqscape software was used for the comparative analysis of mutations of the gene sequences [26] with the standard wild type gene.

GenotypeMTBDRplus VER2.0 assay

The MTBDRplus VER2.0 assay (Hain Lifescience, Nehren, Germany) is a line probe strip assay with DNA probes that detects MTBC and resistance to rifampin and isoniazid. The assay was performed on decontaminated samples using previously standardized protocol [27]. This assay was used as a gold standard for comparison with our sequencing method. The assay has in-built controls where a confirmed result is indicated by the appearance of 5 control zones on each strip; an amplification control zone (AC);a conjugate control zone (CC) and three locus control zones (rpoB for rifampin resistance and katG and inhA for isoniazid resistance). The sample was categorized as resistant when both the mutation probes and the corresponding wildtype probe stained positive.

Statistical analyses

To calculate reaction efficiency of TBSURE, serial dilutions of DNA of known concentration were prepared and multiplex PCR was carried out. A standard curve was prepared using Ct vs log DNA dilution to obtain a straight line. The slope of this line was calculated and used in the formula to give ‘E’. Reaction efficiency was calculated by using the formula: (E-1) x 100%. The reaction efficiency was found to be 103.59%. The sensitivity (true positive rate) and specificity (true negative rate) of TBSURE was calculated by using the formulae, TP / (TP+FN) and TN / (FP + TN) respectively, where TP stands for True positive, FN stands for False negative and TN stands for True negative samples. Specificity and sensitivity was calculated for different groups of samples tested by TBSURE and GeneXpert as well as TBSURE and culture. The positive predictive value (PPV) and negative predictive value (NPV) of TBSURE was calculated by using the formulae: (No. of true positives/(No. of true positives + No. of false positives) and (No. of true Negatives)/(No. of true negatives+ No. of false negatives) respectively.


TBSURE Real time PCR results interpretation

The results of a completed test were considered reliable if the test samples and the control samples met the following criteria. The sensitivity and direct positive PCR should give amplification curve for both NTM (JOE) and MTBC (FAM). The Direct PCR negative control should not give any amplification. The negative sample preparation water controls should show amplification for only IAC and not for NTM/MTBC. The IAC should give expression in all the samples except for the ones having inhibitors. The expression of IAC is checked by the melt curve analysis wherein the melting temperature should be 85.7 ºC +/- 2.5 ºC. A clinical sample which shows amplification for MTBC (FAM) having a Ct value below the sensitivity control (Ct value: 37.3) is considered positive for MTBC infection and a clinical sample which shows amplification curve for NTM(Ct value below 37.3) and not for MTBC is considered positive for NTM infection. All the MTBC/NTM negative samples and negative sample preparation controls should have positive expression of IAC.

Table 2 shows the result interpretation for signals obtained in the three channels and Figure 2 shows representative graphs for all the four combinations of signals obtained in the three channels.

- - + - ve NTM/MTBC
- + + +ve NTM, – ve MTBC
+ + + +ve MTBC, –ve NTM
+/- +/- - Inhibitors present, repeat sample

Table 2: TBSURE real time PCR results interpretation tab


Figure 2: Real-time amplification curves for MTBC (red) and NTM (green) using 16S rRNA, IS6110 and MPB64 gene in FAM and JOE channel. Amplification curves for MTBC (A), amplification curves for NTM (B), amplification curves for negative sample with no MTBC/NTM (C) and amplification curves if inhibitor of PCR is present in sample (D).

Limit of detection (LOD)

The limit of detection was calculated by the method described in Materials and Methods section. The LOD value for the test varies between 6-20 bacteria per test. This test was done for six different bacterial cultures and six different NTM cultures, so as to check reproducibility also.

Sensitivity and specificity

On comparison with GeneXpert, the sensitivity of TBSURE came out to be 92% and specificity came out to be 91%. On comparison with AFB culture, the sensitivity and specificity of the TBSURE came out to be 93.1% and 96.5% respectively. Tables 3-5 show percentage concordance of results when same sample was tested by TBSURE and AFB culture, TBSURE and GeneXpert and by all the three tests respectively. PPV and NPV calculated for different groups of samples tested by TBSURE and Culture was 0.58 and 0.98 and when calculated for TBSURE and GeneXpert was 0.89 and 0.93 respectively.

Variant No. of Samples % Share
TBSURE -ve, Culture –ve 2527 84.17
TBSURE +ve, Culture +ve 201 6.71
TBSURE -ve, Culture +ve 33 1.1
TBSURE +ve, Culture –ve 143 4.76
TBSURE NTM, Culture NTM 47 1.56
TBSURE NTM, Culture –ve 51 1.7
Total 3002 100

Table 3: Variants obtained by EPTB samples tested by TBSURE and culture.

Variant No. of Samples % Share
TBSURE +ve,Xpert MTB/RIF +ve 242 41.3
TBSURE +ve, Xpert MTB/RIF –ve 30 5.2
TBSURE -ve, Xpert MTB/RIF +ve 22 3.7
TBSURE NTM, Xpert MTB/RIF –ve 2 0.4
TBSURE +ve, Xpert MTB/RIF Inhibition 2 0.3
TBSURE -ve, Xpert MTB/RIFInhibition 1 0.1
TBSURE –ve, Xpert MTB/RIF –ve 285 49
Total 585 100

Table 4: Variants obtained by EPTB samples tested by TBSURE and Xpert MTB/RI assay.

Variant No. of Samples % Share
TBSURE -ve, Xpert MTB/RIF-ve, Culture –ve 47 38.5
TBSURE +ve, Xpert MTB/RIF +ve, Culture +ve 22 18
TBSURE +ve, Xpert MTB/RIF+ve, Culture -ve 10 8.2
TBSURE -ve, Xpert MTB/RIF +ve, Culture +ve 6 4.9
TBSURE +ve,Xpert MTB/RIF +ve, Culture -ve 20 16.4
TBSURE –ve, Xpert MTB/RIF –ve, Culture +ve 6 4.9
TBSURE +ve, Culture +ve, Xpert MTB/RIF-ve 6 4.9
TBSURE –ve, Culture –ve, Xpert MTB/RIF+ve 5 4.1
Total 122 100

Table 5: Variants obtained by EPTB samples tested by TBSURE, Xpert MTB/RIF assay and culture.


For any diagnostic test to be validated for diagnosis of any disease, the most important parameters are repeatability, robustness and reproducibility as elaborated in ISO 17025 and Principles and methods of validation of diagnostic assays [28]. In 1998, the STOP TB initiative was started with aim to eliminate TB from the world, in order to accomplish this aim the rapid and accurate diagnosis of TB became the most important prerequisite. Under this initiative, a core group called the New Diagnostics working group was established [29]. Foundation for Innovative Diagnosis (FIND), is a non-profit organization working for developing new diagnostics for poverty related diseases like TB, malaria etc. Xpert MTB/RIF assay done on the machine GeneXpert was developed by FIND in collaboration with Professor David Alland at the University of Medicine and Dentistry of New Jersey (UMDNJ) and Cepheid Inc., Sunnyvale, CA, USA. This is a cartridge based diagnostic assay that gives sensitivity of 81.3% and specificity of 99.8% for EPTB samples of different anatomic origins [30]. This system and its cartridge is available at concessional rates for many developing countries, but still the cost remains excessively high (Table 6).

Variant No. of Samples % share
Sequencing –ve, Xpert MTB/RIF–ve, Hain -ve 81 74.3
Sequencing +ve, Xpert MTB/RIF+ve, Hain +ve 17 15.6
Sequencing +ve, Xpert MTB/RIF–ve, Hain -ve 4 3.7
Sequencing –ve, Xpert MTB/RIF +ve, Hain +ve 1 0.9
Sequencing +ve, Xpert MTB/RIF +ve, Hain -ve 2 1.8
Sequencing –ve, Xpert MTB/RIF–ve, Hain +ve 1 0.9
Sequencing +ve, Hain +ve, Xpert MTB/RIF–ve 2 1.8
Sequencing –ve, Hain –ve, Xpert MTB/RIF+ve 1 0.9
Total 109 100

Table 6: Rifampin resistance determination by Sequencing, XpertMTB/RIF and Hain assay.

In this study, we have developed an improved, indigenous, affordable and sensitive molecular diagnostic test for TB, called ‘TBSURE’ which uses 16S rRNA, IS6110 and MPB64 gene targets in a multiplex real-time PCR format. This is the first in-house reliable, rapid method that distinguishes between MTBC and NTM. NTM infections are becoming increasingly prevalent globally, due to immunodeficiency, hospital exposures and cosmetic procedures [31]. The precise differentiation of MTBC from NTM is essential as the antibiotic susceptibilities of different species of NTMs are very different from that of MTBC. For treatment of TB, it is important to identify the correct antibiotics for early commencement of treatment [32]. It is important to study NTMs because immune response to NTM infection may influence responsiveness to currently used BCG vaccination, especially in paediatric cases [33]. Multiplex PCR using IS6110/hsp65 and duplex PCR targeting regions different between rpoB gene of MTBC and NTM has been used by different groups for MTBC/NTM differentiation between 476 and 78 samples respectively [31,34]. Here in this study, we have employed far more sensitive multiplex real time PCR, TBSURE on a large no. of EPTB samples i.e. 3709 samples and got highly promising results.

The advantage of using multiplex real-time PCR is that it can also be used on samples which are inadequately stored as it requires just the DNA of the bacteria, while this is not the case with phenotypic tests. Moreover, microbiological diagnoses like culture and phenotypic tests often take more than three weeks’ time, and the diagnosis still fails to distinguish between MTBC and NTM and does not give reliable results for drug susceptibility. TBSURE gives a reliable result in not more than 2 h after DNA extraction. In addition to this, we have also used sequencing to find out rifampin resistance in RRDR region with a sensitivity of 93.1% and specificity of 96.5% in wide variety of EPTB samples, when compared to culture. Figure 3 summarises the validation of TBSURE on 3,709 clinical samples.


Figure 3: Clinical validation of TBSURE test. TBSURE is an efficient and affordable alternative for EPTB diagnosis. Validation studies on a total of 3709 clinical samples obtained from patients suspected of EPTB was performed. On comparing 3002 clinical samples with TBSURE and culture method, a sensitivity of 93.1% and specificity of 91.5% was obtained. Comparing 585 clinical samples with TBSURE and Xpert MTB/RIF assay, a sensitivity of 92% and a specificity of 91.5% were obtained. A comprehensive study on 122 clinical samples using TBSURE, Culture and Xpert MTB/RIF assay was performed to assess concordance among three tests. For elucidating rifampin resistance; a comparative validation study on additional 109 clinical samples was done using Sanger Sequencing, Xpert MTB/RIF assay and Hain assay.


WHO issued a policy update on use of XpertMTB/RIF assay for TB detection in adults and children which estimated pooled specificities and sensitivities of different studies across the globe [35]. The sensitivity of the assay in CSF samples, lymph nodes and gastric fluid samples came out to be 79.5%, 83.7% and 83.8%, respectively, while all these gave a good specificity of greater than 98% [35]. The TBSURE test gives a comparable sensitivity (93.1%) and a decent specificity (96.5%), making it an affordable alternative. A single reaction by our in-house PCR along with rifampin resistance test is cheaper than XpertMTB/RIF assay. Ultimately TBSURE test can be transferred to a solid platform to develop a unique single test diagnostics system that distinguishes between MTBC and NTM, which can provide clinician with first hand reliable data that can be used to start correct treatment of infected individual and at the same time provide unamibiguous EPTB cases for epidemiological data of the country.


This work is supported by Department of Science and Technology (DST), Govt. of India. AB is recipient of UGC-BSR Senior Research Fellowship. RG would like to acknowledge DST- INSPIRE Faculty Award scheme.

Compliance with Ethical Standards

All the experiments on virulent mycobacterial cultures were done in DBT sponsored BSL3 Laboratory, School of Biotechnology, Jawaharlal Nehru University, New Delhi. All the experiments on human samples were done in compliance with the guidelines of Good Society for Ethical Research, Shahdra, New Delhi, India (approval no.: GSER/ 2015/ND/AP/045). Prior consent was taken from all the patients for using their samples for research purposes.


This work was supported by Department of Science and Technology, Govt. of India via Grant no. IV-D&P/390/11-12/TDT(G).

Conflict of Interest

The authors declare that they have no conflict of interest. All authors have seen and approved the submission. This manuscript or any related work has not been communicated or is being considered elsewhere.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 1283
  • [From(publication date):
    March-2017 - Dec 12, 2017]
  • Breakdown by view type
  • HTML page views : 1204
  • PDF downloads : 79

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version